Treatment Innovation & Treatment Technology

Treatment technology is at the heart of fundamental restructuring of the health and human service system, particularly in sectors serving consumers with the most complex needs. Tech-enabled treatment has the potential to improve clinical decision making and consumer outcomes, as well as reduce unnecessary administrative burdens. Historically, the health and human service system does not have a great executive bench for understanding and assessing the plethora of new technology options—leaving the “science to service” gap larger than ever. However, as payers look for innovative approaches that go beyond traditional forms of treatment, provider organizations must step up to the challenge and leverage new technologies and virtual delivery systems that engage and empower consumers.

Latest Resources

• Residential Care Reboot 
• Meant Health Expands Telehealth Access To FDA-Approved GLP-1 Prescriptions, Including Ozempic
• Research That Matters: Reduced Emergency Department Use Among Insured Individuals Receiving Extended-Release Buprenorphine In A Health System Setting
• Research That Matters: Recovery From Opioid Use Disorder (OUD) After Monthly Long-Acting Buprenorphine Treatment: 12-Month Longitudinal Outcomes From RECOVER, An Observational Study
• Research That Matters: Patient-Reported Outcomes Of Treatment Of Opioid Dependence With Weekly & Monthly Subcutaneous Depot Vs. Daily Sublingual Buprenorphine, A Randomized Clinical Trial
• Considerations For The Regulation Of Generative AI-Enabled Medical Devices: Discussion Paper & Request For Feedback
• Community Action Treatment (CAT) Team By Bridgeway Center, Inc.: An OPEN MINDS Program Profile
• Configuring Your EHR To Optimize Quality Data: Building the Foundation for Better Insights
• FDA Selects Four Digital Health Companies For TEMPO Pilot; Two Focus On Behavioral Health
• Armor Health & Stark County, Ohio Sheriff’s Office Partner To Launch Jail-Based PATH Program
• MouthPad, The First-Ever Tongue Trackpad, Launches To The Public Alongside New Vox Invisible Keyboard
• Limbic Becomes First AI-Led Mental Health Care Company Selected For FDA TEMPO Pilot
• HaloScape Collaborates With Canary Speech To Integrate Vocal Analysis Technology For Mental Health Status Into A Health Intelligence Platform
• Radial Acquires Mindful Health Solutions To Expand Its Clinical Mental Health Network
• Conscientia Health Launches Virtual Primary Care Services Integrating Mental & Physical Care

FDA Approves Simtriyo As ADHD Medication

On July 24, 2026, the U.S. Food and Drug Administration (FDA) approved a new type of medication for attention-deficit/hyperactivity disorder (ADHD). The medication, called Simtriyo® (centanafadine) and developed by Otsuka Pharmaceutical Development & Commercialization, Inc. and Otsuka Pharmaceutical Co., Ltd. (Otsuka), is the first and only approved norepinephrine, dopamine, serotonin reuptake inhibitor (NDSRI) for ADHD and introduces a new treatment approach for the condition. It is expected to be commercially available later in 2026 following… Read

To sign-up for monthly Treatment Innovation & Treatment Technology alerts, you must be signed in to your account.